Immunology of Neurological Gene Therapy: How T Cells Modulate Viral Vector-Mediated Therapeutic Transgene Expression Through Immunological Synapses

Neurotherapeutics

Volumn 4, Issue 4, 2007, Pages 715-724

  Lowenstein, Pedro R ^a   Kroeger, Kurt ^a   Castro, Maria G ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Gene therapy; immune responses; immunological synapse; neuroimmunology; viral vectors

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; BETA GALACTOSIDASE; BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE DECARBOXYLASE; LEVODOPA; NEURTURIN; VIRUS VECTOR;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; ARTICLE; AUTOIMMUNE DISEASE; BRAIN DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DEGENERATIVE DISEASE; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; NERVE DEGENERATION; NEUROIMMUNOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BRAIN DISEASES; GENE THERAPY; GENETIC VECTORS; HUMANS; T-LYMPHOCYTES; TRANSGENES; VIRUSES;

EID: 34848905068     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2007.07.010     Document Type: Article

References (57)

1. Rogaeva E., Meng Y., Lee J.H., et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39 (2007) 168-177
2. Levi-Montalcini R. The nerve growth factor 35 years later. Science 237 (1987) 1154-1162
3. Rosenberg M.B., Friedmann T., Robertson R.C., et al. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science 242 (1988) 1575-1578
4. Eriksdotter Jonhagen M., Nordberg A., Amberla K., et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 9 (1998) 246-257
5. Tuszynski M.H., Thal L., Pay M., et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11 (2005) 551-555
6. Hardman C.D., Henderson J.M., Finkelstein D.I., Horne M.K., Paxinos G., and Halliday G.M. Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output, internal relay, and striatal modulating nuclei. J Comp Neurol 445 (2002) 238-255
7. Hodaie M., Neimat J.S., and Lozano A.M. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies. Neurosurgery 60 (2007) 17-28 discussion 28-30
8. During M.J., Kaplitt M.G., Stern M.B., and Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 12 (2001) 1589-1591
9. Kaplitt M.G., Feigin A., Tang C., et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369 (2007) 2097-2105
10. Muramatsu S., Fujimoto K., Ikeguchi K., et al. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 13 (2002) 345-354
11. Wong L.F., Goodhead L., Prat C., Mitrophanous K.A., Kingsman S.M., and Mazarakis N.D. Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications. Hum Gene Ther 17 (2006) 1-9
12. Lin L.F., Doherty D.H., Lile J.D., Bektesh S., and Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 (1993) 1130-1132
13. Hyman C., Hofer M., Barde Y.A., et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 350 (1991) 230-232
14. Torres E.M., Monville C., Lowenstein P.R., Castro M.G., and Dunnett S.B. Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors Increased yield of dopamine cells is dependent on embryonic donor age. Brain Res Bull 68 (2005) 31-41
15. Suwelack D., Hurtado-Lorenzo A., Millan E., et al. Neuronal expression of the transcription factor Gli1 using the Tα1 alpha-tubulin promoter is neuroprotective in an experimental model of Parkinson's disease. Gene Ther 11 (2004) 1742-1752
16. Dass B., Kladis T., Chu Y., and Kordower J.H. RET expression does not change with age in the substantia nigra pars compacta of rhesus monkeys. Neurobiol Aging 27 (2006) 857-861
17. Georgievska B., Kirik D., and Bjorklund A. Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J Neurosci 24 (2004) 6437-6445
18. U.S. National Institutes of Health, ClinicalTrials.gov. Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 For Efficacy and Safety in Subjects With Idiopathic Parkinson's Disease [Internet]. Available at: http://www.clinicaltrials.gov/ct/show/NCT00400634?order=1. Accessed June 15, 2007.
19. Suwelack D., Hurtado-Lorenzo A., Millan E., et al. Neuronal expression of the transcription factor Gli1 using the Tubulin a-1 promoter is neuroprotective in an experimental model of Parkinson's disease. Gene Ther 11 (2004) 1742-1752
20. Mochizuki H., Hayakawa H., Migita M., et al. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci U S A 98 (2001) 10918-10923
21. Crocker S.J., Wigle N., Liston P., et al. NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease. Eur J Neurosci 14 (2001) 391-400
22. Dong Z., Wolfer D.P., Lipp H.P., and Bueler H. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol Ther 11 (2005) 80-88
23. Lo Bianco C., Schneider B.L., Bauer M., et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci U S A 101 (2004) 17510-17515
24. Thomas C.E., Birkett D., Anozie I., Castro M.G., and Lowenstein P.R. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther 3 (2001) 36-46
25. Zirger J.M., Barcia C., Liu C., et al. Rapid upregulation of interferon-regulated and chemokine mRNAs upon injection of 108 international units, but not lower doses, of adenoviral vectors into the brain. J Virol 80 (2006) 5655-5659
26. Dewey R.A., Morrissey G., Cowsill C.M., et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 5 (1999) 1256-1263
27. McMenamin P.G. Distribution and phenotype of dendritic cells and resident tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat brain as demonstrated in wholemount preparations. J Comp Neurol 405 (1999) 553-562
28. Pashenkov M., Teleshova N., and Link H. Inflammation in the central nervous system: the role for dendritic cells. Brain Pathol 13 (2003) 23-33
29. Cserr H.F., and Knopf P.M. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 13 (1992) 507-512
30. Bechmann I., Galea I., and Perry V.H. What is the blood-brain barrier (not)?. Trends Immunol 28 (2007) 5-11
31. Cartmell T., Southgate T., Rees G.S., Castro M.G., Lowenstein P.R., and Luheshi G.N. Interleukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain. J Neurosci 19 (1999) 1517-1523
32. Stevenson P.G., Hawke S., Sloan D.J., and Bangham C.R. The immunogenicity of intracerebral virus infection depends on anatomical site. J Virol 71 (1997) 145-151
33. Matyszak M.K., and Perry V.H. The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. Neuroscience 74 (1996) 599-608
34. Matyszak M.K. Inflammation in the CNS: balance between immunological privilege and immune responses. Prog Neurobiol 56 (1998) 19-35
35. Knopf P.M., Harling-Berg C.J., Cserr H.F., et al. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: tissue entry and local retention of antigen-specific B cells. J Immunol 161 (1998) 692-701
36. Caux C., Ait-Yahia S., Chemin K., et al. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 22 (2000) 345-369
37. Leon B., Lopez-Bravo M., and Ardavin C. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26 (2007) 519-531
38. McMahon E.J., Bailey S.L., Castenada C.V., Waldner H., and Miller S.D. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11 (2005) 335-339
39. Aloisi F., and Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6 (2006) 205-217
40. Gerdes C., Xiong C., Chemin W., et al. Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells may be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. Neuron Glia Biol 2 (2007) 309-327
41. Barcia C., Thomas C.E., Curtin J.F., et al. In vivo mature immunological synapses forming SMACs mediate clearance of virally infected astrocytes from the brain. J Exp Med 203 (2006) 2095-2107
42. Thomas C.E., Schiedner G., Kochanek S., Castro M.G., and Lowenstein P.R. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci U S A 97 (2000) 7482-7487
43. Xiong W., Goverdhana S., Sciascia S.A., et al. Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol 80 (2006) 27-37
44. O'Neal W.K., Zhou H., Morral N., et al. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol Med 6 (2000) 179-195
45. Mian A., Guenther M., Finegold M., Ng P., Rodgers J., and Lee B. Toxicity and adaptive immune response to intracellular transgenes delivered by helper-dependent vs. first generation adenoviral vectors. Mol Genet Metab 84 (2005) 278-288
46. Parks R., Evelegh C., and Graham F. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 6 (1999) 1565-1573
47. Maione D., Della Rocca C., Giannetti P., et al. An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus. Proc Natl Acad Sci U S A 98 (2001) 5986-5991
48. Barcia C., Jimenez-Dalmaroni M., Kroeger K.M., et al. Sustained, one year expression from high-capacity helper-dependent adenoviral vectors delivered to the brain of animals with a pre-existing systemic anti-adenoviral immune response: implications for clinical trials. Mol Ther (2007) (in press)
49. Cemerski S., Das J., Locasale J., et al. The stimulatory potency of T cell antigens is influenced by the formation of the immunological synapse. Immunity 26 (2007) 345-355
50. Dustin M.L., and Cooper J.A. The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling. Nat Immunol 1 (2000) 23-29
51. Friedl P., den Boer A.T., and Gunzer M. Tuning immune responses: diversity and adaptation of the immunological synapse. Nat Rev Immunol 5 (2005) 532-545
52. Grakoui A., Bromley S.K., Sumen C., et al. The immunological synapse: a molecular machine controlling T cell activation. Science 285 (1999) 221-227
53. Huppa J.B., and Davis M.M. T-cell-antigen recognition and the immunological synapse. Nat Rev Immunol 3 (2003) 973-983
54. Huse M., Lillemeier B.F., Kuhns M.S., Chen D.S., and Davis M.M. T cells use two directionally distinct pathways for cytokine secretion. Nat Immunol 7 (2006) 247-255
55. Lee K.H., Holdorf A.D., Dustin M.L., Chan A.C., Allen P.M., and Shaw A.S. T cell receptor signaling precedes immunological synapse formation. Science 295 (2002) 1539-1542
56. Monks C.R., Freiberg B.A., Kupfer H., Sciaky N., and Kupfer A. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395 (1998) 82-86
57. Barcia C., Thomas C., Zirger J., et al. Immune system regulation of transgene expression in the brain 1: systemically activated immune responses silence adenoviral vector-encoded transgene expression in the brain through both non-cytolytic and cytotoxic mechanisms. Mol Ther 9 Suppl 1 (2004) 174-175